Halikas J A, Crosby R D, Nugent S M
Department of Psychiatry, University of Minnesota School of Medicine, Minneapolis.
Psychopharmacol Bull. 1992;28(3):315-8.
The Halikas-Crosby Drug Impairment Rating Scale for Cocaine (HAL DIRS-C) is designed to measure improvement in drug treatment through interval assessment of impact of cocaine use on daily functioning, relationships with other people, other alcohol and drug use, cocaine withdrawal symptoms, adverse effects associated with cocaine use, and personal outlook over the previous week. The scale is a 25-item clinical rating scale administered in the context of a semistructured interview (modeled after and similar to the Hamilton Rating Scale for Depression). The HAL DIRS-C was administered weekly to 147 subjects participating in a 12-week, double-blind medication trial with a psychosocial treatment component. Without breaking the pharmacologic blind, the HAL DIRS-C score was found to be significantly related to study retention, ongoing psychosocial treatment participation, urinalysis results, and other measures of outcome. The results support the validity of the HAL DIRS-C as a standardized measure of improvement or outcome in clinical research involving the treatment of cocaine abuse.
哈利卡斯 - 克罗斯比可卡因药物损害评定量表（HAL DIRS - C）旨在通过对可卡因使用对日常功能、与他人关系、其他酒精和药物使用、可卡因戒断症状、与可卡因使用相关的不良反应以及前一周个人前景的影响进行间隔评估，来衡量药物治疗的改善情况。该量表是一个包含25个条目的临床评定量表，在半结构化访谈的背景下进行施测（以汉密尔顿抑郁评定量表为蓝本并与之类似）。HAL DIRS - C每周对147名参与一项为期12周、具有心理社会治疗成分的双盲药物试验的受试者进行施测。在不打破药物盲态的情况下，发现HAL DIRS - C得分与研究保留率、持续的心理社会治疗参与度、尿液分析结果以及其他结局指标显著相关。这些结果支持了HAL DIRS - C作为涉及可卡因滥用治疗的临床研究中改善或结局的标准化测量工具的有效性。
